Impact of Microvascular Inflammation on Kidney Allograft Outcome
1 other identifier
observational
6,000
5 countries
19
Brief Summary
Graft microvascular inflammation poses a significant challenge to successful kidney transplantation due to its heterogeneous clinical presentation. There is a critical need to unravel the clinical significance of newly defined allograft microvascular inflammation phenotypes in the Banff 2022 classification and assess the implications of these new phenotypes on kidney transplant precision diagnostics and patient risk stratification.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2023
Shorter than P25 for all trials
19 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2023
CompletedFirst Submitted
Initial submission to the registry
July 3, 2024
CompletedFirst Posted
Study publicly available on registry
July 11, 2024
CompletedJuly 11, 2024
July 1, 2024
12 months
July 3, 2024
July 3, 2024
Conditions
Outcome Measures
Primary Outcomes (2)
Microvascular inflammation-related diagnoses according to the Banff 2022 Classification
March 2004 to December 2023
Kidney allograft loss
March 2004 to December 2023
Secondary Outcomes (2)
Transplant glomerulopathy
March 2004 to December 2023
(Recurrent) antibody-mediated rejection episode
March 2004 to December 2023
Interventions
No intervention
Eligibility Criteria
Kidney transplant recipients of all sexes recruited in observational studies performed in Europe and United States, with at least one kidney biopsy performed with all the relevant data to provide a diagnosis according to the 2019 and 2022 Banff classification, including clinical data (recipient and donor's age, sex and transplant characteristics).
You may qualify if:
- Kidney transplant recipients, with at least one kidney transplant biopsy performed, assessed with the Banff classification.
You may not qualify if:
- Missing data for a rejection-related diagnosis according to the 2019 and 2022 Banff classification.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (19)
Pediatric Nephrology, UCLA Mattel Children's Hospital
Los Angeles, California, 90095, United States
Division of Pediatric Nephrology, Children's Pediatric Institute
Atlanta, Georgia, 30329, United States
Division of Pediatric Nephrology, Children's Mercy Hospital
Kansas City, Missouri, 64108, United States
Acute Dialysis Units, Pediatric Kidney Transplant
Charleston, South Carolina, 29425, United States
Division of Pediatric Nephrology and Hypertension, Le Bonheur Children's Hospital
Memphis, Tennessee, 38103, United States
Department of Pediatrics, Seattle Children's Hospital
Seattle, Washington, 98105, United States
Division of Nephrology, Department of Medicine, University of Wisconsin School of Medicine and Public Health
Madison, Wisconsin, 53705, United States
Bordeaux University Hospital, Department of Nephrology, Transplantation, Dialysis and Apheresis
Bordeaux, France
Department of Transplantation, Nephrology and Clinical Immunology, Hospices Civils de Lyon
Lyon, France
Department of Nephrology, Centre Hospitalier Universitaire de Montpellier
Montpellier, France
Nantes University Hospital, Department of Nephrology
Nantes, France
Division of Pediatric Nephrology, Necker Hospital, AP-HP
Paris, France
Division of Pediatric Nephrology, Robert Debré Hospital, AP-HP
Paris, France
Kidney Transplant Department, Necker Hospital, Assistance Publique - Hôpitaux de Paris
Paris, France
Kidney Transplant Department, Saint-Louis Hospital, Assistance Publique - Hôpitaux de Paris
Paris, France
Department of Nephrology-Dialysis-Transplantation, Centre Hospitalier Universitaire de Toulouse
Toulouse, France
Department of Nephrology and Critical Care Medicine, Charité - Universitätsmedizin Berlin, Freie Universität Berlin, Berlin Institute of Health
Berlin, Germany
Department of Nephrology and Kidney Transplantation, Vall d'Hebrón University Hospital
Barcelona, Spain
Division of Abdominal and Transplantation Surgery, Department of Surgery, Geneva University Hospitals,
Geneva, Switzerland
Related Publications (1)
Sablik M, Sannier A, Raynaud M, Goutaudier V, Divard G, Astor BC, Weng P, Smith J, Garro R, Warady BA, Zahr RS, Twombley K, Dharnidharka VR, Dandamudi RS, Fila M, Huang E, Sellier-Leclerc AL, Tonshoff B, Rabant M, Verine J, Del Bello A, Berney T, Boyer O, Catar RA, Danger R, Giral M, Yoo D, Girardin FR, Alsadi A, Gourraud PA, Morelon E, Le Quintrec M, Try M, Villard J, Zhong W, Bestard O, Budde K, Chauveau B, Couzi L, Brouard S, Hogan J, Legendre C, Anglicheau D, Aubert O, Kamar N, Lefaucheur C, Loupy A. Microvascular Inflammation of Kidney Allografts and Clinical Outcomes. N Engl J Med. 2025 Feb 20;392(8):763-776. doi: 10.1056/NEJMoa2408835. Epub 2024 Oct 24.
PMID: 39450752DERIVED
Study Officials
- PRINCIPAL INVESTIGATOR
Alexandre Loupy
Paris Institute for Transplantation and Organ Regeneration
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
July 3, 2024
First Posted
July 11, 2024
Study Start
January 1, 2023
Primary Completion
December 31, 2023
Study Completion
December 31, 2023
Last Updated
July 11, 2024
Record last verified: 2024-07